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 Coronary artery disease (CAD) presents itself with significant frequency in the 
human population across the globe. The acute condition affects in some form, almost half 
of the middle aged male population in the US.  The chronic condition develops over time 
to finally evolve into the acute state which presents itself as chest pain and results in a 
myocardial infarction. The field of biochemistry has discovered a risk factor, 
homocystein thiolactone (Hcy-thiolactone), that plays a rule in exacerbating the chronic 
and acute processes of CAD. Mechanistic theory and experimentation reveals that 
Paraoxinase I is capable of negating Hcy-thiolactone’s pathologic effects. Manipulation 
of PON1 shows promise in reducing the risk of the acute phase of CAD development. A 
patient case study is provided that illustrations a common presentation of the acute 
condition. An understanding of the identification and treatment process with regard to the 





 I have much gratitude to Dr. Josh Baker for supervising my research endeavor and 
providing useful insight on researching my mechanistic aspect of the disease. I would 
also like to show my appreciation for Tenille Smith MSIV, whose instruction guided the 
successful formation of my case study. Finally I want to thank Gina Sella for her 




Table of Contents 
 Abstract……………………………………………………………………………i 
 Acknowledgements…………………………………………………………….….ii 
 Table of Contents……………………………………………...………………….iii 
 List of Tables……………………………………………………………………...v 
 List of Figures…………………………………………………………………….vi 
 Chapter 1: Disease Review 
o Introduction………………………………………………………………..1 
o Clinical Features and Symptoms………………………………………….1 
o Risk Factors……………………………………………………………….3 
o Pathophysiology…………………………………………………………...3 
o Diagnostic Testing and Diagnosis………………………………………...7 
o Treatment………………………………………………………………...10 
o Review of Disease………………………………………………………..12 
o Conclusion……………………………………………………………….12 
 Chapter 2: The Cardioprotective Role of Paraoxinase 1 in HDL via Hydrolysis of 
Homocysteine Thiolactone, A Risk Factor for Cardiovascular Disease 
o Introduction………………………………………………………..……..13 
o Methods and Results………………………………………………….….20 
o Discussion………………………………………………………………..24 
 Chapter 3: A Case Study…………………………………………………………26 
o Chief Complaint………………………………………………………….26 
o History of Present Illness………………………………………….……..26 
iv 
 
o Review of Systems…………………………………………………...…..27 
o Past Medical History………………………………………………….….27 
o Surgical History……………………………………...…………………..28 
o Family History…………………………………………………………...28 
o Social History…………………………………………………………….28 
o Current Medications………………………………………….…………..28 
o Allergies………………………………………………………………….28 
o Physical Exam……………………………………………………………28 
o Diagnostic studies………………………………………………………..30 
o Medical Decision Making…………………………………………….….34 




List of Tables 
Table 1. HTase reactivation with respect to the addition of various metals…………….21 
Table 2. How different substrates are accepted by the different conformations of  





List of Figures 
Figure 1. Cross section of an artery illustrating leukocyte migration……………………..4 
Figure 2. Plaque rupture with imminent thrombosis……………………………………...6 
Figure 3. Biomarkers of acute myocardial infarction……………………………………..8 
Figure 4. ST segment elevation, depression, and T wave inversion on an ECG………….9 
Figure 5. Pathophysiological hypothesis of homocysteine thiolactone………………….14 
Figure 6. Error-editing reaction where methionyl-tRNA mistakenly selects homocysteine  
    and converts it to Hcy-thiolactone…………………………………...………..15 
Figure 7. General mechanism of N-homocysteinylation of proteins by Hcy-thiolactone by  
    reacting with the lysine residue of a protein…………………………………..17 
Figure 8. N-Hcy-protein levels with respect to HTase activity in vitro and human blood  
   plasma………………………………………………………………………….20 
Figure 9. Recombinant PON1 variant G6E2…………………………………………...22 
Figure 10. Proposed active site and catalytic mechanism of PON1……………………..22 
Figure 11. HDL-SH formation with respect to Hcy-thioloactone concentration….......…23 
 
Figure 12. 12 lead EKG………………………………………………….………………32 
 
Figure 13. Chest xray…………………………………………………………………….33 
 










An overview of coronary artery disease has been formed including the clinical 
presentation and treatment of the condition as well as the pathophysiology. The condition 
may present itself acutely or chronically, both of which are explored in great detail which 
regard to signs and symptoms as well as treatment plans. The pathophysiology of the 
chronic state and how it leads to the acute state is outlined. A molecular mechanism is 
introduced that has implications in CAD.  
 Coronary artery disease is a condition that may be benign at first and can prove 
fatal over time. It is responsible for the largest number of deaths around the world and as 
such is a condition being vigorously researched and treatments being developed. 
Examination of the inflammatory roots of the disease’s pathophysiology will give insight 
into the current treatment options available. 
Clinical Features and Symptoms 
 
The hallmark symptom of CAD is angina pectoris, or simply chest pain, and is 
sometimes visualized with the patient clutching their chest in severe or acute situations. 
Varying levels of angina pectoris exist with the least concerning being low risk or stable 
angina and the most concerning being high risk or unstable angina. Stable angina is 
specifically defined as having no significant change in frequency, duration, precipitating 
causes, or ease of relief. Usually this can be managed for at least 60 days without any 
complication but unstable angina arises when chest pain that was previously chronic has 
an increase in frequency and/or duration. New triggers to the chest pain as well as the 
inability to relieve the pain with past successful therapies elicit the consideration of 
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unstable angina. Patient’s having chest pain for the first time or presenting with evidence 
of recent myocardial damage must be considered in the unstable angina category until 
further evaluation. Normally patients with stable angina can be treated under the 
observation of their primary care physician. However, unstable angina is of greater 
severity and is usually referred to a cardiologist by the primary care physician. 
 Instances in which the chest pain is acute, and most of the time severe, falls into 
the hands of emergency medicine and is categorized as acute coronary syndrome. Chest 
pain in these cases is often accompanied by diaphoresis (excess sweating). Other 
accompanying symptoms include upper abdominal pain, back pain, throat/jaw pain, arm 
pain, nausea, shortness of breath, and/or dizziness. Expeditious treatment in the 
emergency department with cardiology consult is critical to patient survival with 
evidence of myocardial damage or dysfunction with diagnostic testing. 
 Significant CAD can also be present in individuals are asymptomatic. This is 
known as silent myocardial ischemia and is discovered by electrocardiogram findings 
pointing at previous myocardial damage. It has been noted that this condition has higher 
prevalence among individuals with diabetes mellitus, older age, prior heart attack history, 
or past revascularization procedures. 
 CAD also presents itself in patients for the first time, although rarely, as sudden 
cardiac death. This is highly acute, difficult to treat, and is best prepared for by 
recognizing people at risk for CAD before allowing this nature of presentation to occur. 
 Studies have shown that the occurrences of CAD are much higher in males than 
females. In the US, signs and symptoms appear in approximately half of middle-aged 
men and one-third of middle aged women. As such, women are generally less likely to be 
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considered at risk for CAD even when presenting with similar symptoms as men. Women 
additionally tend to show the less typical symptoms, such as shortness of breath, 




 Being of the male gender or having a past family history of CAD are factors that 
currently can’t be changed that increase CAD risk. Factors that can be personally 
influenced include tobacco use, hyperlipidema, hypertension, diabetes mellitus, obesity, 
and a sedentary lifestyle. Individuals can reduce their risk for CAD with regard to the 
pervious factors with smoking cessation, diet changes, regular exercise, and medication 
use. Recently evidence has shown the evaluation of lipoprotein A, highly sensitive C-
reactive protein, fibrinogen, and homocystein can aid in earlier treatment and prevention 
of CAD (Hanson et al., 2013). 
Pathophysiology 
 
Several years ago, an overhaul in the causative effects of CAD has shown that the 
atherosclerotic aspect is less indicative of a cholesterol storage problem and more line 
with a chronic inflammatory disorder. Treatment to prevent the chronic lesion formation 
representative of CAD will stop the thrombotic acute phase of the disease. The 
inflammatory component of the disease involves a complex interaction between the cells 
of the artery and the white blood cells in the lumen via various signaling molecules. The 
condition is initiated by bacterial products or risk factors including dyslipidemia, 
vasoconstrictor hormones, the products of glycoxidation associated with hyperglycemia, 
or proinflammatory cytokines derived from excess adipose tissue. These initiators 
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increase the production of signaling molecules on the inner surface of the arterial wall 
which results in an increased leukocyte presence, mainly composed of mononuclear 
phagocytes and T lymphocytes, outside the arterial intima. Chemoattractant cytokines 
induce the transmigration of the leukocytes into the intima as seen in figure 1.  
 
 
Figure 1. Cross section of an artery displaying leukocyte migration. 
Source: Pathophysiology of Coronary Artery Disease 
 
 
Signals associated with risk factors for atherosclerosis regulate these chemoattractant 
cytokines. Inflammatory processes are underway once the leukocytes and endogenous 
cells of the arterial wall communicate. Prostanoids and other derivatives of arachidonic 
acid as well as autacoids such as histamine mediate the inflammatory response. The 
prostanoids play a role in the regulation of communication between cells while histamine 
increases the permeability of the blood vessel. The large increase in activity in the intima 
prompts the entry of smooth muscle cells from the arterial media and the resulting 
acceleration of extracellular matrix development. Matrix metalloproteinases are then 
secreted by smooth muscle cells, endothelial cells, and monocytes which have a role in 
matrix reconstruction of arteries and myocardium. This enlargement of the matrix causes 
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a subsequent increase in lipoprotein binding by proteoglycans. Lipoproteins become 
more vulnerable to oxidative modification and glycation when bound to proteoglycans, 
the products of which exacerbate the inflammatory response. In the midst of Cell 
proliferation and cell death all occur within the lesion. Leukocytes overwhelmed with 
lipid particles die and release tissue factor which elevates thrombotic risk. Sometimes 
calcification similar to process involved in the construction of bone tissue occurs. The 
plethora of lipids accumulating amidst the cell deaths aggregates to structure the 
infamous necrotic plaque. 
Development of the chronic condition over time ultimately leads to the 
presentation of acute coronary syndrome, or the emergent aspect of coronary artery 
disease. Thrombosis is the formation of a blood clot within the blood vessel that increases 
the likelihood of vessel blockage. The thrombotic environment arising from a plaque is 
initiated when the fibrous cap protecting the tissue within the plaque is disrupted. 
Disruption leads to coagulation, thrombosis of the clot, and finally restriction of the blood 
flow. Thrombosis can also be caused by superficial erosion, intraplaque hemorrhage, or 
the erosion of a calcified nodule although they are not too common. The clotting process 
is composed of two elements, the “fluid phase” determinants which increases the 
disposition for clotting and the “solid state” determinants mainly responsible for the acute 
clotting. The “solid state” exists after disruption of the atherosclerotic plaque surface 







Figure 2. Plaque rupture with imminent thrombosis. 
Source: Pathophysiology of Coronary Artery Disease 
 
This contact causes platelet activation and subsequent clotting. Simultaneously, 
macrophages and smooth muscle cells secrete tissue factor that starts the coagulation 
cascade. Development of the thrombus exacerbates the process via positive feedback by 
increasing platelet activation as well as inducing the clotting effects of other cells in the 
plaque. Fibrinogen is soluble in the blood and can be transformed into fibrin which binds 
to each other as insoluble fibers that aid in the clotting process. This along with secretion 
of von Willebrand, a glycoprotein involved with coagulation, create a dense network of 
platelets connected to each other and suspended in a fibrin mesh (Libby & Theroux, 
2005). The high platelet density nature of this thrombus gives it the characteristic “white” 
arterial thrombus appearance contrary to the high blood cell and fibrin composition of the 
“red” venous thrombus. (Jerjes-Sanchez, 2005). Blood levels of fibrinogen, tissue factor 
micro-particles, and Plasminogen Activor Inhibitor 1 (PAI-1) are all categorized under 
the “fluid phase” determinants influencing thrombosis. PAI-1 specifically plays an 
interesting role by suppressing natural processes of the body that disrupt thrombolytic 
presence. Mechanisms that inhibit urokinase-like and tissue-type plasminogen activators, 
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therefore reducing excessive coagulation, are limited to some extent by PAI-1. This leads 
to an increased tendency for clotting to occur and develop and as such displays high 
levels of PAI-1 as a disposition toward coronary artery disease. Diabetes and obesity are 
examples of conditions in which PAI-1 tends to have higher than normal levels in the 
blood stream. (Libby & Theroux, 2005).   
Diagnostic Testing and Diagnosis 
 
The gold standard for diagnosis of CAD is the use of the coronary angiogram. 
However due to its invasiveness and generally high cost, it is normally not the first form 
of testing completed. Lab results, electrocardiogram findings, stress tests, and imaging 
findings are all useful in determining the presence of CAD whether chronic or acute. 
Acute coronary syndrome, aortic dissection, pulmonary embolism, pericarditis, 
gastroesophageal reflux disease, peptic ulcer disease, biliary problems, and 
musculoskeletal causes are all differential diagnoses for acute onset chest pain. 
Lab results give some insight into whether a patient is experiencing an acute 
exacerbation of CAD. Elevated levels of Cardiac biomarkers (myoglobin and CK 
isoforms), troponin, and creatinine kinase MB (CK-MB) may all indicate some extent of 




Figure 3. Biomarkers of acute myocardial infarction. 
Source: Coronary Artery Disease 
 
Unfortunately these results aren’t completely decisive. Myoglobin and CK isoforms can 
be elevated without any occurrence of MI. Increased CK-MD levels can also be 
associated with skeletal myopathy/trauma, cardiac trauma, myocarditis, severe 
hypothyroidism, seizures, cardioversion/defibrillation, and renal failure. Increased 
troponin levels can also be associated with several of the previous conditions as well as 
heart failure, pulmonary embolism, demand ischemia, coronary angioplasty, or 
myocardial infiltration. 
 The electrocardiogram is one of the most commonly utilized cardiac tests and is 
critical for the diagnosis of acute coronary syndrome. Specifically the focus is centralized 





Figure 4. ST segment elevation, depression, and T wave inversion on an ECG 
Source: Coronary Artery Disease 
 
Elevated ST segments indicate cardiac ischemia although a lack of elevation may not 
necessarily it out. Some depression in ST segments along with T-wave inversion points at 
unstable angina. The presence of Q waves indicates the patient may have had a past 
myocardial infarction.  
 Stress tests allow the heart to be evaluated while under the conditions of exertion 
and utilize the ECG as well as blood pressure observation throughout the test. Patients 
asymptomatic of CAD may develop those symptoms while under stress. Exertional 
hypotension will occur if there is severe heart failure or if CAD as affecting multiple 
vessels of the heart. Fixed cardiac output, volume depletion, and the effects of 
vasodilators can also result in exertional hypotension. The opposing condition of 
exertional hypertension is not as informative of a finding as exertional hypotension but 
does indicate a higher chance for developing hypertension. In cases where patients are 
unable to complete a stress test due to orthopedic or medical issues, their heart can be 
stimulated to imitate conditions of exertions with Dobutamine being a commonly used 
stimulant. 
 The level of calcium detected in the coronary arteries of the heart, scored 
according to the Agatson score, gives an idea of the risk a patient has to develop CAD. 
This is due to the common presence of calcium in atherosclerotic plaques characteristic 
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of CAD. The technique is completed by having a CT scan of the heart done followed by 
determination of the Agatson score. A score of 0 means there is no identifiable disease, 1-
99 shows mild disease, 100-399 shows moderate disease, and 400+ shows severe disease. 
 Cardiac catheterization and angiography is the most informative diagnostic 
method in that it displays the heart’s blood flow status in real time. The procedure is 
completed by catheter insertion via blood vessels in the groin, arm, or neck and 
movement to the vessels of the heart. From there a dye is injected and imaging of the 
blood flow is taken to show the efficiency of blood flow through the vessels and heart 
and whether there is any sort of obstruction. The angiogram is merely for imaging but 




A patient presenting with the acute version of CAD should be given oxygen, 
aspirin, β – blockers, nitrates, and morphine given that they do not have any 
contraindications against any of those treatments. Continuous observation is also a must 
with the use of constant ECG, blood pressure, and oxygen saturation monitoring. This 
allows for immediate detection of abnormal heart rhythms, rates, and heart failure.  
Aspirin acts as a blood thinner and so reduced the coagulation ability of the blood 
and consequently alleviating a thrombotic environment. The recommended dosage for 
acute CAD is orally chewed 162 to 325 mg. Clopidogrel must be taken simultaneously if 
the patient has an allergy to aspirin. β – blockers decrease heart rate and strength of 
contractions which reduces stress on the left ventricular wall and cardiac oxygen demand. 
It is usually given intravenously for acute cases. Contraindications for β – blockers 
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include cardiogenic shock, moderate to severe LV failure, second- or third-degree 
atrioventricular heart block, hypotension with systolic blood pressure less than 100 mm 
Hg, sinus bradycardia with heart rate less than 69, or severe reactive airway disease. 
Nitrates, specifically nitroglycerin, is administered sublingually for the first dosage and 
intravenously for following dosages. Its function is the relaxation of smooth muscle 
which reduces left ventricular preload stress, dilates coronary vessels, and reverses 
vasospasms. Morphine is a pain medication administered intravenously during episodes 
of acute coronary syndrome. Supplemental oxygen provides a plethora of oxygen for the 
body to utilize so that ischemia due to a lack of oxygen in the environment is not an 
issue. 
Concrete studies have shown that many acute coronary syndrome cases with ST 
segment elevation are caused by thrombosis to the coronary vessels, blockage, and 
resulting ischemia. As such, the use of blood thinners, or medications that decrease 
clotting efficiency, have been essential to reducing the effects of thrombosis related 
myocardial infarction. The physical widening of blocked vessels, known as angioplasty, 
is another technique used to treat acute coronary syndrome. Stents are wire meshes that 
hold the structure of vessels and keep them open. 
The chronic CAD condition does not require immediate intervention but can be 
treated over a period of time. The use of aspirin, β – blockers, nitrates, calcium channel 
blockers, and statins allow for chronic alleviation of CAD and reduction of risk factors. 
Procedural treatments include angioplasty, stent placement, coronary artery bypass 




Review of Disease 
 
In the past, the treatment and prevention of coronary artery disease was focused 
on cholesterol metabolism and storage but has now moved to a more inflammatory 
perspective. Extensive research has begun with the thrombosis aspect of the disease 
including how people with increased risk for thrombosis are at increased risk for CAD. 
Recent studies centering around homocysteine (Hcy) and its erred modification to 
homocysteine thiolactone have revealed the connection of these proteins to CAD risk. 
Homocysteine thiolactone, created via and error in an editing reaction of homocysteine, 
causes homocysteinylation (N-Hcy-“protein”) of various proteins. The 
homocysteinylation of fibrinogen (N-Hcy-fibrinogen) in particular transforms normal 
fibrinogen into version more resistant to lysis. The result is a circulatory system more 
prone to coagulation and consequential ischemia (Jakubowski, 2008). 
Conclusion 
 
The machinations of CAD are becoming more and more translucent with much more 
treatment capability today than decades ago. The critically acute onset now can still be 
treated for and with a lower mortality rate. However, increased awareness of the 
manifestation of CAD will better equip the population to prevent or diagnose and treat 
the disease. Research is still ongoing to further elucidate the causes of CAD and 




Chapter 2: The Cardioprotective Role of Paraoxinase 1 in HDL via Hydrolysis of 
Homocysteine Thiolactone, A Risk Factor for Cardiovascular Disease. 
Introduction 
The pathological consequences of homocysteine thiolactone (Hcy-thiolactone) in 
CAD have focused research on the enzyme responsible, PON1, for reducing Hcy-
thiolactone’s negative effects. Several correlative studies, both in laboratory and clinical 
settings, have been completed that display PON1’s biochemical relationship with Hcy-
thiolactone. Directed evolution has been used to create variants of PON1 that have been 
used to discover the structure of PON1 and a likely mechanism of hydrolysis of Hcy-
thiolactonase. Ironically, a study has shown how PON1 possibly undergoes N-
homocysteinylation itself. Research focusing on increasing the expression of PON1 by 
hyperactivation of the enzyme or overexpression of the gene in humans shows promise 
into reducing the risk of CAD development or exacerbation. 
Now that research has expanded from the cholesterol storage aspects of coronary 
artery disease and into the inflammatory aspects, much attention is being brought to 
methods of alleviating the inflammation state. Thrombosis occurs with disruption of the 
inflammation site, a plaque in an arterial wall, where contents within the plaque spew into 
the bloodstream causing coagulation and the formation of a thrombus. Regulation of a 
person’s thrombotic tendencies shows promise into regulating, to some extent, coronary 
artery disease itself. This is where homocysteine thiolactone (Hcy-thiolactone) presents 
itself as a causal agent of coronary artery disease with respect to the coagulation 
component. Simultaneously, Paraoxinase 1 (PON 1) presents itself as an enzyme known 
to have a detoxification role in the human body with the proposed hydrolysis of Hcy-
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thiolactone. Discovering the natural mechanism of degrading Hcy-thiolactone opens the 
way to inducing Paraoxinase 1 to specifically increase hydrolysis of Hcy-thiolactone or 
discovering artificial methods of reducing Hcy-thiolactone levels. 
Homocysteine is an intermediate molecule in the metabolic pathways of methionine and 
cysteine as seen in figure 5. 
 
 
Figure 5. Pathophysiological hypothesis of homocysteine thiolactone 
Source: The pathophysiological hypothesis of homocysteine thiolactone-mediated 
vascular disease 
 
It is formed from methylation reactions from methionine with first the activation of 
methionine by ATP to form S-adenosylmethionine (AdoMet). Transfer of a methyl group 
from AdoMet forms S-adenosylhomocysteine (AdoHcy) and a following hydrolysis 
converts AdoHcy into Hcy. At this point, Hcy can be remethylated to methionine 
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catalyzed by Met synthase with vitamin B12 as a cofactor and 5,10-mthyl-tetrahydrofolate 
as a reactant. Hcy can also undergo a transsulferation to cysteine starting with the help of 
cystathionine β-synthase (CBS) with vitamin B6 as a cofactor. The pathophysiological 
relevance of homocysteine to CAD starts when homocysteine does not undergo the 
normal remethylation or transsulfuration reactions and instead is accidentally selected by 
methionyl-tRNA synthetase (MetRS) in an error-editing reaction in protein biosynthesis 
as seen in figure 6.  
 
  
Figure 6. Error-editing reaction where methionyl-tRNA mistakenly selects homocysteine 
and converts it to Hcy-thiolactone 
Source: The pathophysiological hypothesis of homocysteine thiolactone-mediated 
vascular disease 
 
The accidental selection of homocsyteine by MetRS results in the metabolism of the 
thioester, homocysteine thiolactone. The reaction involves MetRS interacting with 
homocysteine at its active site and using ATP to catalyze the formation of the thioester.  
Genetic mutations that cause enzymes involved in the remethylation or transsulfuration 
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of homocysteine to become altered increases the flux through the Hcy-thiolactone 
pathway. The condition in which homocysteine is produced in excessive levels in the 
blood plasma is called hyperhomocysteinemia and it was the examination of this 
condition that led researchers to discover the causal relationship between homocysteine 
and subsequently homocysteine thiolactone and vascular disease. Increased levels of 
homocysteine and the consequent Hcy- thiolactone have been found to be strongly 
correlated with vascular problems, including atherothrombosis (Jakubowski, 2008). One 
study found that baboons given diets enriched with Hcy-thiolactone or direct Hcy-
thiolactone infusions have had a higher rate of atherosclerosis development when 
compared to baboons with normal diets (Harker et al, 1947). Another study’s results 
displayed a positive correlation between the presence of Hcy-thiolactone and the 
initiation of apoptosis in human vascular endothelial cells (Kerkeni et al, 2006). First 
developed in 1997, the Hcy-thiolactone hypothesis explains that the pathological issues 
caused by an increase in homocysteine are due to the conversion to Hcy-thiolactone and 
its resulting behavior. It is common to find heightened levels of Hcy-thiolactone in 
patients predisposed to atherothrombosis and so further validates the theory. Several 
mechanisms of Hcy-thiolactone that create an environment favoring atherothrombosis 
include modification of proteins by homocysteinylation, oxidative stress, inflammation, 
endothelial dysfunction, and thrombosis. Hcy-thiolactone’s ability to induce a form of 
protein modification known as N-homocysteinylation is due to its nature as a reactive 
metabolite. The modification itself occurs with the formation of amide bonds with lysine 





Figure 7. General mechanism of N-homocysteinylation of proteins by Hcy-thiolactone by 
reacting with the lysine residue of a protein 
Source: The pathophysiological hypothesis of homocysteine thiolactone-mediated 
vascular disease 
 
N-homocysteinylation causes a protein to lose its functionality or leads to an alteration of 
its functionality. One protein in particular that undergoes this transformation by Hcy-
thiolactone is fibrinogen and N-Hcy-fibrinogen it was first discovered in vitro in human 
fibroblasts and endothelial cells (Jakubowski, 2000). N-Hcy-fibrinogen along with other 
affected proteins have been found in increased quantities in aortic lesions of mice with 
hyperhomocysteinemia with the use of anti-N-Hcy-protein antibodies (Perła-Kaján, 
2008). Vascular lesions are the foundation upon which the inflammatory aspect of 
coronary artery disease takes hold. This relation between vascular lesions, N-Hcy-
proteins, and a large presence of homocysteine solidifies the Hcy-thiolactone pathway as 
a causal agent of CAD. This relation is cemented further more from the positive 
correlations between N-homocysteinylation of proteins and the triggering of the auto-
immune response and increasing vascular inflammation. N-Hcy-fibrinogen presents a role 
more critical than that of other proteins in increasing thrombotic tendencies in human 
vasculature. This was determined when it was discovered that blood clots, composed of 
fibrinogen, degraded more slowly when the fibrinogen was exposed to Hcy-thiolactone 
and allowed to undergo N-homocysteinylation. It is proposed that the altered protein is 
able to sustain the clot formation for a longer period of time because the N-
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homocysteinylation affects lysine resides that are near the sites for activating and binding 
plasminogen. Consequently, plasminogen has a hard time being converted to plasmin and 
gaining the ability to break apart blood clots. This mechanistic hypothesis for fibrinogen 
alteration can be supported by a correlation between the negative effects of high plasma 
Hcy-thiolactone levels and lessened dissolution capability of blood clots. With N-Hcy-
fibrinogen a building block to a sturdier form of vascular clotting, it is evident that Hcy-
thiolactone’s mechanism of N-homocysteinylation is a major culprit in the thrombotic 
elements of CAD. N-Hcy-proteins in general serve as an exacerbating agent of 
autoimmunogenicity in humans by instigating the formation of IgG auto-antibodies that 
target N-Hcy-Lys epitopes. CAD and stroke patient’s especially display a strong 
correlation between elevated levels of anti-N-Hcy proteins and anti-N-Hcy-protein IgG 
auto-antibodies. Another strong correlation is revealed between plasma homocysteine 
levels and Anti-N-Hcy-protein auto-antibodies, showing that the increased presence of 
homocysteine leads to Hcy-thiolactone formation and subsequent transformation of 
proteins. Any protein that has undergone homocysteinylation is at risk of being bound by 
the IgG auto-antibodies and then being formed into antigen-antibody complexes. The 
auto-immune response elicited by N-Hcy-proteins has pathological implications in CAD 
when these complexes arise on the surfaces of blood vessels. Macrophages phagocytize 
endothelial cells covered in the complexes with the antibodies exposed.  This results in 
vascular damage and is followed by lesions when the surface is repeatedly repaired. With 
lesions being the foundation of CAD, it can be seen how detrimental the presence of 
these auto-antibodies can be to CAD patients (Jakubowski, 2008). 
 Fortunately a molecule exists, Paraoxinase 1 (PON1), which is naturally able to 
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hydrolyze Hcy-thiolactone in the human body. It was initially discovered and named for 
its ability to hydrolyze the oganosphosphate paraoxon. PON1’s relation to atherosclerosis 
arose when it came to light that its presence affected the outcome of atherosclerosis in 
mice. Mice deficient in PON1 would develop atherosclerosis more frequently than wild 
type mice when on high fat diets. Contrarily, transgenic mice that have three copies of the 
human PON1 gene would be less likely to develop atherosclerosis (Jakub, 2008). Several 
correlative studies, both in laboratory and clinical settings, have been completed that 
display PON1’s biochemical relationship with Hcy-thiolactone. Directed evolution has 
been used to create variants of PON1 that have been used to discover the structure of 
PON1 and a likely mechanism of hydrolysis of Hcy-thiolactonase. Ironically, a study has 










Figure 8. N-Hcy-protein levels with respect to HTase activity in vitro and human blood 
plasma. In vitro N-Hcy-protein levels with respect to HTase activity (Left). Human blood 
plasma N-Hcy-protein levels with respect to human serum HTase activity (Right). The in 
vivo data was obtained by measuring plasma N-Hcy-protein levels and HTase activity in 
cystathionin β-synthase-deficient patients. The in vivo data was obtained by radioactively 
labeling Hcy-thiolactone. 






Table 1. HTase reactivation with respect to the addition of various metals. 
Source: Calcium-dependent Human Serum Homocysteine Thiolactone Hydrolase: A 






Figure 9. Recombinant PON1 variant G6E2. Directed evolution was used to create the 
recombinant PON1 variant G6E2 for experimentation to simulate human PON1. The 
structure was determined using xray crystallography. Two calcium ions are displayed as 
green spheres in the center of the molecule along with the phosphate ion as a red stick 
model. 
Source: 3-D Structure of Serum Paraoxonase 1 Sheds Light on Its Activity, Stability, 




Figure 10. Proposed active site and catalytic mechanism of PON1. Determined from 
analysis of the structure in figure 6. 
Source: 3-D Structure of Serum Paraoxonase 1 Sheds Light on Its Activity, Stability, 
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Table 2. How different substrates are accepted by the different conformations of PON1 





Figure 11. HDL-SH formation with respect to Hcy-thioloactone concentration. The 
increase over time in –SH groups in HDL incubated when exposed to three 
concentrations of Hcy-thiolactone [10 µmol/L (square), 100 µmol/L (diamond); and 1 
mmol/L (triangle) Hcy-thiolactone] 
Source: Effect of Homocysteinylation on Human High-density Lipoproteins: A 








PON1 has been found to be associated with apolipoprotein A1 on an HDL particle 
(Jakubowski 2012). This allows for some experimentation with the PON1 enzyme by 
using HDL particles since PON1 is unstable and usually aggregates when not in the 
presence of detergents (Harel et al, 2007). Therefore the activity level of PON1 can still 
be observed without removal from the HDL complex and displays an interesting 
correlation with respect to N-Hcy-protein levels as can be seen in Figure 4. There is a 
strong negative correlation between the activity level of an HTase protein, PON1, and N-
Hcy-protein levels in vivo in the human blood serum as well as when the same conditions 
are replicated in vitro. This cements the foundation of PON1’s role in reducing N-Hcy-
protein levels via a mechanism somewhere in the homocysteinylation pathway (Perla-
Kaján, 2010). Analysis of the enzyme with respect to reactivation by metals (Figure 5) 
shows that calcium plays a major functional role in the PON1’s ability to reduce N-Hcy-
protein levels. This inference can be made from the fact that the enzyme reactivates with 
a significantly high frequency in the presence of calcium ions when compared to other 
metals (Jakubowski, 2000). Determining the reason for PON1’s dependence on calcium 
requires a visualization of the enzyme which can be seen in Figure 6. The two calcium 
ions lie in the center of the enzyme along with a phosphate ion and compose the catalytic 
aspect of the enzyme. Figure 7 shows a catalytic mechanism of the active site, which 
includes an upper calcium ion, a phosphate ion, and a histidine dyad, for substrates such 
as phenyl and 2-naphthylacetate (Harel et al, 2007). This gives insight into the active 
site’s multi-substrate functionality and further experimentation reveals that PON1 is 
found in a closed formation when hydrolyzing aliphatic lactones, specifically Hcy-
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thiolactone. One suggestion is that the Try71 of PON1 interacts with the lactone ring 
while Ile74 interacts with the alkyl side chain of Hcy-thiolactone to hold it in place for 
hydrolysis (Perla-Kaján, 2012). Interestingly, it has been discovered that PON1 can 
undergo homocysteinylation, and subsequent inactivation, by Hcy-thiolactone. Figure 9 
shows how the percentage of sulfhydryl groups present in an incubating HDL solution 
increase with the increased concentration of Hcy-thiolactone. Since the formation of 
sulfhydryl groups is an indicator of Hcy-thiolactone activity, it shows how PON1 itself 
can be victim to homocysteinylation. Research focusing on increasing the expression of 
PON1 by hyperactivation of the enzyme or overexpression of the gene in humans shows 







Chapter 3: A Case Study 
 
The case study presented here follows the treatment and diagnosis of a 56 year old 
Caucasian male presenting with acute chest pain. Acute coronary syndrome, which 
commonly presents itself as chest pain, affects in some form almost half of the middle 
aged male population in the US. The frequency with which this condition afflicts people 
highlights the importance of being able to identify and treat the condition in various 
levels of the medical field. This case study serves the purpose of illustrating a general 
manner in which this acute condition can be addressed and resolved. 
Leo Cichlid 
Chief Complaint 
Leo Cichlid presents to the emergency department with a chief complaint of chest 
pain. 
History of Present Illness 
Leo Cichlid is a 56 year old Caucasian male with a history of hypertension 
complaining of constant sharp central chest pain onset about an hour ago. He reports he 
has been having intermittent chest pains over the past month with a severity of 6/10 that 
lasts about thirty seconds. He states these episodes of chest pain appear to be provoked by 
exertion and generally resolve after 30 seconds with rest. Leo states today he was 
mowing his lawn when he started to feel the chest pain again but this time with a severity 
of 8/10. He reports his chest pain has been constant and was radiating to his left arm at 
onset but not currently. He states the pain was intense for the first 30 min and is still 
present now but slightly less severe. Leo reports his current chest pain is also exacerbated 
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with exertion. He states he had associated diaphoresis and mild shortness of breath. He 
denies he has had any palpitations, leg swelling, nausea, vomiting, hematemesis, 
abdominal pain, melena, headache, fever, cough, sputum production, or hemoptysis. Leo 
reports he has a history of hypertension but denies he has any history of heart attacks, 
pulmonary embolism, deep vein thrombosis, COPD, or diabetes. He states he normally 
takes a 75 mg aspirin every day but hasn’t been taking them over the past week because 
he ran out. He denies having any past surgeries. Leo denies any history of family 
members dying at a young age (before age 60) from heart attacks. He reports he has no 
known allergies. He states he has been smoking about a quarter pack of cigarettes a day 
for the past 20 years. Leo states he drinks alcohol occasionally but denies any drug use, 
particularly cocaine or methamphetamine. 
Review of Systems 
Constitutional: Positive for diaphoresis. Negative for fever. 
Cardiovascular: Positive for sharp central chest pain. Negative for palpitations. 
Pulmonary: Positive for mild shortness of breath. Negative for cough, sputum production, 
or hemoptysis. 
Gastrointestinal: Negative for nausea, vomiting, hematemesis, abdominal pain, or 
melena. 
Musculoskeletal: Positive for left arm pain. Negative for leg swelling. 
Neurologic: Negative for headache. 
Past Medical History 
Hypertension. 







Denies any history of family members dying at a young age (before age 60) from heart 
attacks. 
Social History 
Smokes about a quarter pack of cigarettes a day with a 5 pack-year history. 
Drinks alcohol occasionally. 
Denies any drug use, particularly cocaine or methamphetamine. 
Current Medications 
Daily aspirin (75 mg). 
Allergies 
No known allergies. 
Physical Exam 
Vital signs: 
Oxygen saturation: 96% Heart rate: 74  Blood pressure: 137/84 
Respiratory rate: 12  Temperature: 98.3
o
F  Height: 5’11’’  
Weight: 180 pounds 
Exam findings: 
Constitution: Well developed, Well nourished, Not obese, Alert, Mild distress. 
HENT: No signs of trauma, Bilateral external ears normal, Bilateral TM’s normal, 
Oropharynx moist and without exudates, Nose normal.  
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Eyes: Pupils are equal and reactive, Conjunctiva normal, Non-icteric.  
Neck: Supple, Trachea midline, Normal range of motion, No tenderness.  
Lymphatic: No lymphadenopathy noted.  
Cardiovascular: Regular rate and rhythm, No murmurs. Point of maximal impact is not 
laterally displaced. 
Thorax & Lungs: Normal breath sounds, Mild respiratory distress, No wheezing, No 
chest tenderness to palpation. 
Abdomen: Bowel sounds normal, Soft, No tenderness, No rebound, No guarding, No 
masses, No pulsatile masses.  
Skin: Warm, Dry, No erythema, No rash, Koi fish tattoo on the upper back. 
Back: No bony tenderness, No CVA tenderness.  
Extremities: Intact distal pulses, No edema, No tenderness, No cyanosis, Negative 
Homans’ sign. 
Musculoskeletal: Good range of motion in all major joints. No tenderness to palpation or 
major deformities noted.  
Neurologic: Awake and alert x3, Normal motor function, Normal sensory function, No 
focal deficits noted.  








     Patient values   Normal range 
 
Complete Blood Count: 
 
RBC     4.7 x 10
12 




Hemoglobin    16 g/dL   14-17 g/dL (Male) 
 
Hematocrit    48%    41-51 % (Male) 
 
MCV     92 fL    80-100 fL 
 
MCH     29.7 pg   28-32 pg 
 
MCHC    33.3 g/dL   32-36 g/dL   
 
White Cell Count   4.3 x 10
9




Neutrophil Count (Absolute)  2.4 x 10
9




Neutrophil Count (Relative)  56.2 %    50.0-62.0 % 
 
Band neutrophils (Absolute)  1.9 x 10
8




Band neutrophils (Relative)  4.4 %    3.0-6.0 % 
 
Lymphocyte (Absolute)  1.4 x 10
9




Lymphocyte (Relative)  33.5 %    25.0-40.0 % 
 
Monocyte Count (Absolute)  1.5 x 10
8




Monocyte Count (Relative)  3.5 %    3.0-7.0 % 
 
Eosinophil Count (Absolute)  9.0 x 10
7




Eosinophil Count (Relative)  2.1 %    0.0-3.0 % 
 
Basophil Count (Absolute)  1.3 x 10
7




Basophil Count (Relative)  0.3 %    0.0-1.0 % 
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Patient values   Normal range 
 
Platelet Count    260 x 10
9




MPV     9.4 fL    7.5-11.5 fL 
 
Comprehensive Metabolic Panel: 
 
Albumin    4.5 g/dL   3.9-5.0 g/dL 
 
Alkaline phosphatase   84 IU/L   44-147 IUL 
 
ALT     22 IU/L   8-37 IUL 
 
AST     17 IU/L   10-34 IU/L 
 
BUN     10 mg/dL   7-20 mg/dL 
 
Calcium    9.1 mg/dL   8.5-10.9 mg/dL 
 
Chloride    98 mmol/L   96-106 mmol/L 
 
     Patient values   Normal range 
 
CO2     25 mmol/L   20-29 mmol/L 
 
Creatinine    1.2 mg/dL   0.8-1.4 mg/dL 
 
Glucose    83 mg/dL   70-100 mg/dL 
 
Potassium    4.0 mEq/L   3.7-5.2 mEq/L 
 
Sodium    137 mEq/L   136-144 mEq/L 
 
Total bilirubin    0.4 mg/dL   0.2-1.9 mg/dL 
 
Total protein    7.8 g/dL   6.3-7.9 g/dL 
 
Prothrombin Time:   13.0 seconds   11-13.5 seconds  
 
Partial Thromboplastin Time:  33 seconds   25-35 seconds 
 
Troponin T:    0.80 ng/mL   0-0.10 ng/mL  
 
Brain Natriutetic Peptide Test: 280 pg/mL   0-100 pg/mL 
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Patient values   Normal range 
 






Figure 12. 12 lead EKG. A 2 mm ST segment elevation is present in lead aVR and 1 mm 
ST segment elevation is present in lead V1. Diffuse ST segment depressions are present 
in leads V2-V6, I aVI, II, and aVF. 








Figure 13. Chest xray. The radiologist interpreted the chest xray as normal with no acute 
findings. 






Figure 14. Coronary angiogram. The left main coronary artery was found to be in stenosis 
with a 40 % occlusion. 




Medical Decision Making 
Differential Diagnoses: 
When a chief complaint of chest pain presents itself clinically it is usually first suspected 
of being cardiac in nature. However, pulmonary and gastrointestinal sources must also be 
taken into account. Several differential diagnosis and the reasoning behind their 
consideration follow: 
Acute coronary syndrome (myocardial infarction) is of high probability 
considering the acute nature of the patient’s chest pain as well as his history of 
hypertension and smoking cigarettes. If ACS is the case, the patient may currently be 
having a heart attack or had one since onset of the chest pain. 
Unstable angina is another possibility as seen by the increase in intensity of the 
chest pain that he has been feeling over the past month. This presentation may signify 
risk for myocardial infarction (Unstable Angina: MedlinePlus Medical Encyclopedia, 
2012). 
Aortic dissection usually occurs when the inner lining of the aorta separates from 
the other layers, causing bleeding into the open space. It often presents with acute severe 
chest pain although usually as a tearing or ripping quality. The patient’s history of 
hypertension is a risk factor (Aortic Dissection: MedlinePlus Medical Encyclopedia, 
2012). 
Pulmonary embolism is the sudden blockage of an artery in the lungs and may 
cause chest pain similar to a heart attack. The patient’s history of smoking gives him 
some predisposition to blood clot formation although he states he has had no history of 
blood clots (DVT or PE). He also appears to have no leg swelling or pain which is 
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indicative of DVT and normally precedes PE (Pulmonary Embolism: MedlinePlus 
Medical Encyclopedia, 2014). 
Pericarditis occurs when the pericardium becomes inflamed and usually presents 
with chest pain. It is often caused by infection and the initial indication appears weak 
since the patient has no associated fever (Pericarditis: MedlinePlus Medical 
Encyclopedia, 2012). 
Pneumonia can culminate into chest pain but is commonly associated with 
coughing, sputum production, fever, shortness of breath and/or chills. It can lead to sepsis 
and so has reasonable concern but the patient doesn’t appear to illustrate this 
(Pneumonia: MedlinePlus Medical Encyclopedia, 2014). 
Boerhaave syndrome (esophageal rupture) is the perforation of the esophagus, 
causing chest pain and difficulty swallowing. The patient has a weak indication of this as 
he has no history of GI procedures since most ruptures are caused by injury during such 
procedures. He also has had no violent vomiting or chest trauma (Esophageal perforation: 
MedlinePlus Medical Encyclopedia, 2012). 
Costocondritis is a common cause of chest pain and results from the inflammation 
of the cartilages connecting the ribs to the sternum. This is a very weak differential as the 
patient had no tenderness with palpation of the chest wall (Costochondritis: MedlinePlus 
Medical Encyclopedia, 2012). 
Diagnosis and Treatment: 
 The patient’s symptoms raised high concern for a cardiac pathophysiology and he 
was immediately put on supplemental oxygen via a nonrebreather (Hanson et. al, 2013).  
He was also immediately treated with PO chewable aspirin, IV metoprolol, PO sublingual 
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nitroglycerin, and IV morphine since he had no contraindications. Aspirin was used to 
inhibit blood clotting. Metoprolol was used to reduce the patient’s blood pressure, treat 
his chest pain, and to increase outpatient survival in case he was having a myocardial 
infarction. Nitroglycerin reduces the chance of ischemia by relaxing the heart muscles. 
Morphine was given for pain control and to reduce anxiety. The EKG completed soon 
after patient arrival displayed ST segment elevations indicative of possibly a left main 
coronary artery occlusion or at least some form of myocardial infarction. A prompt 
bedside chest X-ray showed the patient had no signs of esophageal rupture or pneumonia 
such as airspace opacity. With initial medications administered and the cardiologist 
consulting, the patient was taken off to the catheter lab to have an angiogram. Critical lab 
results resulted showing the patient had increased Troponin T, B-Type Natriutetic 
Peptide, and C-reactive Protein levels which further solidified the idea the patient was 
having a heart attack. The lab results showed no signs of infection from the presence of 
his various blood cells. His electrolytes were at normal levels as well indicating normal 
kidney and liver function. With the angiogram, the patient’s was found to have a 40 % 
occlusion of the left main coronary artery and a diagnosis of coronary artery disease and 
myocardial infarction. He was immediately taken to emergency coronary bypass surgery. 
Complications from a coronary artery bypass graft include heart muscle damage, 
arrhythmia development, bleeding, renal failure, and/or wound infection. The patient did 
not have any acute complications during his procedure. He was admitted to the hospital 
for observation and rehabilitation. The patient was discharged five days later with 
prescriptions for an anticoagulant, a beta blocker, an ACE inhibitor, a nitrate, and a statin 
medication. He followed up with his new cardiologist and was put on a preventative plan 
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to avoid subsequent heart attacks and for wound care to avoid infection. He was 
specifically put on medications to treat his hypertension and given a statin to reduce CAD 
risk. Leo followed his chronic treatment plan accordingly and finally heeded his primary 
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